This is an excerpt from the April 16 PR: Kevetr
Post# of 72444
(Total Views: 363)
Posted On: 07/31/2019 9:02:27 AM
This is an excerpt from the April 16 PR:
Kevetrin and Acute Myeloid Leukemia
Building on data presented at the 2017 European Hematological Association (EHA) Annual Meeting by independent cancer researchers and their conclusion—“Our results suggest Kevetrin is a promising new drug in AML patients treatment, both in wild type and, even more, in TP53 mutated tumors, through different molecular mechanisms, giving more therapeutic alternatives in the treatment of this disease.”—the Company has been notified that a related scientific article is under review for publication by a leading oncology journal. The paper details Kevetrin’s treatment potential in Acute Myeloid Leukemia (AML) by targeting p53 and several key leukemia-related genes. AML accounts for approximately one-third of all leukemias worldwide and has a 5-year survival rate of only 25 percent.
Maybe this is the study that the article will be based on. Hope to see a PR reflecting this and a link to the oncology journal.
Kevetrin and Acute Myeloid Leukemia
Building on data presented at the 2017 European Hematological Association (EHA) Annual Meeting by independent cancer researchers and their conclusion—“Our results suggest Kevetrin is a promising new drug in AML patients treatment, both in wild type and, even more, in TP53 mutated tumors, through different molecular mechanisms, giving more therapeutic alternatives in the treatment of this disease.”—the Company has been notified that a related scientific article is under review for publication by a leading oncology journal. The paper details Kevetrin’s treatment potential in Acute Myeloid Leukemia (AML) by targeting p53 and several key leukemia-related genes. AML accounts for approximately one-third of all leukemias worldwide and has a 5-year survival rate of only 25 percent.
Maybe this is the study that the article will be based on. Hope to see a PR reflecting this and a link to the oncology journal.
(5)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼